Labeling requirements for systemic antibacterial drug products intended for human use. Final rule.
The Food and Drug Administration (FDA) is amending its regulations to require that the labeling for all systemic antibacterial drug products (i.e., antibiotics and their synthetic counterparts) intended for human use include certain statements about using antibiotics in a way that will reduce the development of drug-resistant bacterial strains. The final rule reflects a growing concern in FDA and the medical community that unnecessary use of systemic antibacterials has contributed to a dramatic increase in recent years in the prevalence of drug-resistant bacterial infections. The final rule is intended to encourage physicians to prescribe systemic antibacterial drugs only when clinically necessary. The final rule is also intended to encourage physicians to counsel their patients about the proper use of such drugs and the importance of taking them exactly as directed.
D000900:Anti-Bacterial Agents; D003365:Costs and Cost Analysis; D004348:Drug Labeling / Q000191:economics / Q000331:legislation & jurisprudence*; D024881:Drug Resistance, Bacterial; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D000900:Anti-Bacterial Agents